$5.6 Billion Questcor Deal Means High Drug Prices For Everybody

Quote












Wait until you see what a pain in the a$$ reimbursement is for this drug, that is if payers even continue to pay. Then you have all the headaches with free drug and tons of co-pay assistance. bahahaha. All the shady practices, will be fun for all of you
 






Anonymous said:
Wait until you see what a pain in the a$$ reimbursement is for this drug, that is if payers even continue to pay. Then you have all the headaches with free drug and tons of co-pay assistance. bahahaha. All the shady practices, will be fun for all of you
Click to expand...
a complete waste of money. This is where our bonus and marketing money went to. And also were our raises went. We are off to a great start
 












Anonymous said:
You ppl have no clue what drives revenue growth and performance. Seriously, go work somewhere else. Please.
Click to expand...

Spare us your self-righteous bullshit. Questcor is a one-horse company like Cadence and if they ever get patent pressure, all of that money will have been pissed away.

We're buying second-rate companies and will probably end up just like Elan, with a collection of products they could not sell fast enough and too many products with regulatory issues.
 






Anonymous said:
Spare us your self-righteous bullshit. Questcor is a one-horse company like Cadence and if they ever get patent pressure, all of that money will have been pissed away.

We're buying second-rate companies and will probably end up just like Elan, with a collection of products they could not sell fast enough and too many products with regulatory issues.
Click to expand...

No self-righteous bullshit here - perhaps that's yours you're reading into. Again you have no clue about revenue growth and financial performance, much less leadership opportunities in pharma. You must just be a low performing rep with no growth potential. Nice.
 






Anonymous said:
No self-righteous bullshit here - perhaps that's yours you're reading into. Again you have no clue about revenue growth and financial performance, much less leadership opportunities in pharma. You must just be a low performing rep with no growth potential. Nice.
Click to expand...

You must really take your Abilify a few hours before you start posting.

Questcor has one product and not much else. If FDA decides to yank the approvals or require more warnings (which they have done before) or if a biosimilar comes onto the market, then it's all over. Mallinckrotch bought Cadence for over a billion, yet its product loses patent in five years and won't generate enough in sales to cover the purchase price. Real good planning there, skippy.

I sold Acthar HP over 20 years ago, child. It's an old product that dates from the 50s. Given the changes in health care, anyone who thinks that high-priced products like Acthar won't be seriously affected by Medicaid or Medicare reimbursement changes, they are delusional just like you.
 






Top Bottom
Back
Quote